Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies

This article has no abstract
Epistemonikos ID: fe532cf63c962b3d02643b2076c9173210cf71d3
First added on: Feb 07, 2025